0001479290-21-000035.txt : 20210204 0001479290-21-000035.hdr.sgml : 20210204 20210204211557 ACCESSION NUMBER: 0001479290-21-000035 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210202 FILED AS OF DATE: 20210204 DATE AS OF CHANGE: 20210204 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schilke Tobin CENTRAL INDEX KEY: 0001678984 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36297 FILM NUMBER: 21593106 MAIL ADDRESS: STREET 1: 7000 SHORELINE COURT, #371 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Revance Therapeutics, Inc. CENTRAL INDEX KEY: 0001479290 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770551645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1222 DEMONBREUN STREET STREET 2: SUITE 1001 CITY: NASHVILLE STATE: TN ZIP: 37203 BUSINESS PHONE: 510-742-3400 MAIL ADDRESS: STREET 1: 7555 GATEWAY BLVD CITY: NEWARK STATE: CA ZIP: 94560 4 1 wf-form4_161249134328472.xml FORM 4 X0306 4 2021-02-02 0 0001479290 Revance Therapeutics, Inc. RVNC 0001678984 Schilke Tobin C/O REVANCE THERAPEUTICS, INC. 1222 DEMONBREUN STREET, SUITE 1001 NASHVILLE TN 37203 0 1 0 0 CFO Common Stock 2021-02-02 4 A 0 22620 0 A 71419 D Employee Stock Option (Right to Buy) 28.01 2021-02-02 4 A 0 40925 0 A 2031-02-01 Common Stock 40925.0 40925 D The shares subject to the Restricted Stock award shall vest in three (3) equal annual installments beginning from March 15, 2021, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date. The shares subject to the stock option shall vest in forty-eight (48) equal monthly installments beginning from February 2, 2021, subject to Mr. Schilke's Continuous Service (as defined in the Plan) on each vesting date. /s/ Gordon Ho, Attorney-in-Fact 2021-02-04